The rising number of hepatitis infected population is expected to drive the global hepatitis B treatment market during the forecast period :

Pune, India, May 2019 /MRFR Press Release/- Market Research Future published a half-cooked research report on the global hepatitis B treatment market.

Market Highlights

The global hepatitis B treatment market is expected to grow at an approximate CAGR of 5.3% during the forecast period, 2018–2024.
Hepatitis B is a viral infection caused by a hepatitis B virus. This infection lasts for a longer period and can cause many other complications, such as scarring in the liver, liver cancer or liver failure. The person suffering from hepatitis B faces various symptoms such as fever, fatigue, nausea, and muscle aches. The other symptoms include jaundice, swelling in the legs, poor appetite, drowsiness and many more. The key factors contributing the market growth are growing geriatric population, increasing the prevalence of viral infection and growing sexually transmitted diseases among the population contribute to driving the market growth. The World Hepatitis Alliance (WHA), 2017 reported that 52 million children across the world are living with viral hepatitis. Such a huge population suffering from Hepatitis boosts the market growth.
However, the factor such as the side effects or complication caused due to treatment may hamper the market growth. 


Segmentation


The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.


Regional Analysis


The Americas dominates the global market for hepatitis B treatment. Factors such as the presence of a large number of healthcare companies, increasing geriatric population and high healthcare expenditure among the population within the Americas drives the market. The National Vaccine Information Center reported 3,370 cases of hepatitis B were reported in the US in 2015.


Following similar trends, Europe stood second in the global hepatitis B treatment market. The increased prevalence of viral diseases and growing healthcare expenditure in this region boost market growth. Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth. Asia Pacific was the fastest growing region for the global hepatitis B treatment market in 2017. This can be attributed due to the increasing incidences of HIV infection and rising demand for the treatment of viral infection among the population boosts market growth. 


On the other hand, the Middle East and Africa holds the least share in the global hepatitis B treatment market. The poor economies within the African region and lack of awareness about the treatment methods hinder the market growth.

Access Report Details @ https://www.marketresearchfuture.com/reports/hepatitis-b-treatment-market-7817


Key Players


Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and others.